Comparison of Computerized Prescription Support Systems in COVID-19 Patients: INTERCheck and Drug-PIN

The coronavirus disease 19 (COVID-19) infection requires major efforts in healthcare systems, due to the high risk of mortality, particularly in subjects with significant comorbidity (≥ 2 pathologies) and polypharmacy (≥ 5 drugs). The treatment of COVID-19 needs a careful evaluation, to reduce the r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:SN comprehensive clinical medicine 2022, Vol.4 (1), p.3-3, Article 3
Hauptverfasser: Martocchia, Antonio, Bruscia, Clara, Conforti, Giulia, Falangone, Francesca, Marini, Valentina, Pennica, Alfredo, Pezzuto, Aldo, March, Massimiliano Rocchietti, Sentimentale, Alberto, Spuntarelli, Valerio, Tafaro, Laura, Ricci, Alberto, Simmaco, Maurizio, Sesti, Giorgio, Preissner, Robert, Martelletti, Paolo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The coronavirus disease 19 (COVID-19) infection requires major efforts in healthcare systems, due to the high risk of mortality, particularly in subjects with significant comorbidity (≥ 2 pathologies) and polypharmacy (≥ 5 drugs). The treatment of COVID-19 needs a careful evaluation, to reduce the risk of potentially adverse drug reactions. The aim of the study was to examine the use of computerized prescription support in the management and treatment of the COVID-19 infection. We evaluated n.33 patients (51% females) admitted to the west COVID Low-Medium Intensity of Care of Sant’Andrea Hospital during the period March–April 2020 and n.42 subjects (50% females) admitted to the Internal Medicine ward (as control group), by INTERCheck® and Drug-PIN®. The comorbidity (n. pathologies), polypharmacy (n. drugs), and total INTERCheck score in COVID-19 patients and controls were, respectively (mean ± standard deviation): 5.8 ± 3.8, 7.9 ± 4.5, and 9.2 ± 7.1 and 6.8 ± 2.6, 8.0 ± 2.6, and 4.9 ± 3.8 (statistically significant for comorbidity p  
ISSN:2523-8973
2523-8973
DOI:10.1007/s42399-021-01079-9